Allergan PLC intends to discuss with FDA whether the accelerated approval pathway could provide a regulatory lifeline for progesterone vaginal gel 8% for reducing the risk of preterm birth now that the agency, as expected, has issued a “complete response” letter.
During a Feb. 27 analyst conference presentation, Watson President and CEO Paul Bisaro said the company intends to meet with...